Positive News SentimentPositive NewsNASDAQ:KALV KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis $11.90 -0.29 (-2.38%) As of 05/9/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About KalVista Pharmaceuticals Stock (NASDAQ:KALV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KALV alerts:Sign Up Key Stats Today's Range$11.88▼$12.7150-Day Range$10.32▼$13.7752-Week Range$7.30▼$15.50Volume377,248 shsAverage Volume417,540 shsMarket Capitalization$591.62 millionP/E RatioN/ADividend YieldN/APrice Target$24.83Consensus RatingBuy Company OverviewKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Read More… KalVista Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreKALV MarketRank™: KalVista Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 200th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKalVista Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about KalVista Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.56) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KalVista Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.04% of the float of KalVista Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.04 Percentage of Shares Shorted14.04% of the float of KalVista Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News Sentiment1.73 News SentimentKalVista Pharmaceuticals has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for KalVista Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest3 people have searched for KALV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have bought 527.49% more of their company's stock than they have sold. Specifically, they have bought $1,158,500.00 in company stock and sold $184,625.00 in company stock.Percentage Held by Insiders10.50% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about KalVista Pharmaceuticals' insider trading history. Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Stock News HeadlinesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Buys $235,500.00 in StockApril 12, 2025 | insidertrades.comReviewing Verrica Pharmaceuticals (NASDAQ:VRCA) and KalVista Pharmaceuticals (NASDAQ:KALV)May 11 at 1:13 AM | americanbankingnews.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.May 11, 2025 | Brownstone Research (Ad)KalVista: Poised For Rare Disease TransformationApril 12, 2025 | seekingalpha.comKalVista subsidiary licenses commercialization rights for sebetralstat in JapanApril 9, 2025 | markets.businessinsider.comKalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in JapanApril 8, 2025 | uk.finance.yahoo.comKalVista licenses commercialisation rights for HAE to Kaken in JapanApril 8, 2025 | finance.yahoo.comKalVista rises after licensing deal with Kaken for lead asset in JapanApril 8, 2025 | msn.comSee More Headlines KALV Stock Analysis - Frequently Asked Questions How have KALV shares performed this year? KalVista Pharmaceuticals' stock was trading at $8.47 at the start of the year. Since then, KALV stock has increased by 40.5% and is now trading at $11.90. View the best growth stocks for 2025 here. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) announced its earnings results on Thursday, December, 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.01. Who are KalVista Pharmaceuticals' major shareholders? Top institutional investors of KalVista Pharmaceuticals include Vanguard Group Inc. (4.62%), Emerald Advisers LLC (1.81%), Emerald Mutual Fund Advisers Trust (1.22%) and Charles Schwab Investment Management Inc. (0.23%). Insiders that own company stock include Venrock Healthcare Capital Par, Benjamin L Palleiko, Thomas Andrew Crockett, Paul K Audhya, Christopher Yea, Edward P Feener and Albert Cha. View institutional ownership trends. How do I buy shares of KalVista Pharmaceuticals? Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Chevron (CVX) and Netflix (NFLX). Company Calendar Last Earnings12/05/2024Today5/11/2025Next Earnings (Estimated)7/10/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALV CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$24.83 High Stock Price Target$30.00 Low Stock Price Target$19.00 Potential Upside/Downside+108.7%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-103.92% Return on Assets-88.06% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio6.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book2.45Miscellaneous Outstanding Shares49,716,000Free Float44,229,000Market Cap$591.62 million OptionableOptionable Beta0.05 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:KALV) was last updated on 5/11/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.